Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies

Ming Zhao; L. Jeffrey Medeiros; Wei Wang; Guilin Tang; Hai Suk Jung; Steven M. Sfamenos; Hong Fang; Gokce A. Toruner; Shimin Hu; C. Cameron Yin; Pei Lin; Jun Gu; Guang Peng; M. James You; Joseph D. Khoury; Sa A. Wang; Zhenya Tang

doi:10.1016/j.cancergen.2021.12.009

Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies

Ming Zhao, L. Jeffrey Medeiros, Wei Wang, Guilin Tang, Hai Suk Jung, Steven M. Sfamenos, Hong Fang, Gokce A. Toruner, Shimin Hu, C. Cameron Yin, Pei Lin, Jun Gu, Guang Peng, M. James You, Joseph D. Khoury, Sa A. Wang, Zhenya Tang

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

A home-brew, tri-color MECOM breakapart FISH probe with a full MECOM coverage labeled with a separate dye is compared in parallel with a 2-color commercial MECOM breakapart probe in 17 cases of hematologic malignancies. Cases with a typical positive signal pattern (or “balanced” signal pattern) (n = 2) and a negative result (n = 3) using the commercial probe achieved the same results using the new probe (100% concordance), whereas 9 of 12 (75%) remaining cases with an atypical signal pattern (or “unbalanced” signal pattern) using the commercial probe showed a “balanced” signal pattern using the new probe. Three cases with undetermined MECOM rearrangement status by the commercial probe were further clarified with no MECOM rearrangement in 2 cases and presence of a subclone with simultaneous gain and rearrangement of MECOM in 1 case. More importantly, the new probe is capable of determining the presence, location and integrity of MECOM after rearrangement. In conclusion, atypical signal patterns obtained using a commercial FISH probe for MECOM can be solved through re-design and optimization of a new BAP probe, especially in those cases with a true MECOM rearrangement. The potential of the new probe for use in the clinical laboratory will be further investigated.

Original language	English (US)
Pages (from-to)	23-29
Number of pages	7
Journal	Cancer Genetics
Volume	262-263
DOIs	https://doi.org/10.1016/j.cancergen.2021.12.009
State	Published - Apr 2022

Keywords

Fluorescence in situ hybridization (FISH)
MECOM rearrangement
Myeloid neoplasms
Probe design
“unbalanced” signal pattern

ASJC Scopus subject areas

Molecular Biology
Genetics
Cancer Research

Access to Document

10.1016/j.cancergen.2021.12.009

Cite this

Zhao, M., Medeiros, L. J., Wang, W., Tang, G., Jung, H. S., Sfamenos, S. M., Fang, H., Toruner, G. A., Hu, S., Yin, C. C., Lin, P., Gu, J., Peng, G., You, M. J., Khoury, J. D., Wang, S. A., & Tang, Z. (2022). Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies. Cancer Genetics, 262-263, 23-29. https://doi.org/10.1016/j.cancergen.2021.12.009

Zhao, M , Medeiros, LJ , Wang, W , Tang, G, Jung, HS, Sfamenos, SM, Fang, H , Toruner, GA , Hu, S , Yin, CC , Lin, P , Gu, J , Peng, G , You, MJ, Khoury, JD, Wang, SA & Tang, Z 2022, 'Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies', Cancer Genetics, vol. 262-263, pp. 23-29. https://doi.org/10.1016/j.cancergen.2021.12.009

@article{f9c5da014f7049d1acdde38be6b093bf,

title = "Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies",

abstract = "A home-brew, tri-color MECOM breakapart FISH probe with a full MECOM coverage labeled with a separate dye is compared in parallel with a 2-color commercial MECOM breakapart probe in 17 cases of hematologic malignancies. Cases with a typical positive signal pattern (or “balanced” signal pattern) (n = 2) and a negative result (n = 3) using the commercial probe achieved the same results using the new probe (100% concordance), whereas 9 of 12 (75%) remaining cases with an atypical signal pattern (or “unbalanced” signal pattern) using the commercial probe showed a “balanced” signal pattern using the new probe. Three cases with undetermined MECOM rearrangement status by the commercial probe were further clarified with no MECOM rearrangement in 2 cases and presence of a subclone with simultaneous gain and rearrangement of MECOM in 1 case. More importantly, the new probe is capable of determining the presence, location and integrity of MECOM after rearrangement. In conclusion, atypical signal patterns obtained using a commercial FISH probe for MECOM can be solved through re-design and optimization of a new BAP probe, especially in those cases with a true MECOM rearrangement. The potential of the new probe for use in the clinical laboratory will be further investigated.",

keywords = "Fluorescence in situ hybridization (FISH), MECOM rearrangement, Myeloid neoplasms, Probe design, “unbalanced” signal pattern",

author = "Ming Zhao and Medeiros, {L. Jeffrey} and Wei Wang and Guilin Tang and Jung, {Hai Suk} and Sfamenos, {Steven M.} and Hong Fang and Toruner, {Gokce A.} and Shimin Hu and Yin, {C. Cameron} and Pei Lin and Jun Gu and Guang Peng and You, {M. James} and Khoury, {Joseph D.} and Wang, {Sa A.} and Zhenya Tang",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2022",

month = apr,

doi = "10.1016/j.cancergen.2021.12.009",

language = "English (US)",

volume = "262-263",

pages = "23--29",

journal = "Cancer Genetics",

issn = "2210-7762",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies

AU - Zhao, Ming

AU - Medeiros, L. Jeffrey

AU - Wang, Wei

AU - Tang, Guilin

AU - Jung, Hai Suk

AU - Sfamenos, Steven M.

AU - Fang, Hong

AU - Toruner, Gokce A.

AU - Hu, Shimin

AU - Yin, C. Cameron

AU - Lin, Pei

AU - Gu, Jun

AU - Peng, Guang

AU - You, M. James

AU - Khoury, Joseph D.

AU - Wang, Sa A.

AU - Tang, Zhenya

PY - 2022/4

Y1 - 2022/4

N2 - A home-brew, tri-color MECOM breakapart FISH probe with a full MECOM coverage labeled with a separate dye is compared in parallel with a 2-color commercial MECOM breakapart probe in 17 cases of hematologic malignancies. Cases with a typical positive signal pattern (or “balanced” signal pattern) (n = 2) and a negative result (n = 3) using the commercial probe achieved the same results using the new probe (100% concordance), whereas 9 of 12 (75%) remaining cases with an atypical signal pattern (or “unbalanced” signal pattern) using the commercial probe showed a “balanced” signal pattern using the new probe. Three cases with undetermined MECOM rearrangement status by the commercial probe were further clarified with no MECOM rearrangement in 2 cases and presence of a subclone with simultaneous gain and rearrangement of MECOM in 1 case. More importantly, the new probe is capable of determining the presence, location and integrity of MECOM after rearrangement. In conclusion, atypical signal patterns obtained using a commercial FISH probe for MECOM can be solved through re-design and optimization of a new BAP probe, especially in those cases with a true MECOM rearrangement. The potential of the new probe for use in the clinical laboratory will be further investigated.

AB - A home-brew, tri-color MECOM breakapart FISH probe with a full MECOM coverage labeled with a separate dye is compared in parallel with a 2-color commercial MECOM breakapart probe in 17 cases of hematologic malignancies. Cases with a typical positive signal pattern (or “balanced” signal pattern) (n = 2) and a negative result (n = 3) using the commercial probe achieved the same results using the new probe (100% concordance), whereas 9 of 12 (75%) remaining cases with an atypical signal pattern (or “unbalanced” signal pattern) using the commercial probe showed a “balanced” signal pattern using the new probe. Three cases with undetermined MECOM rearrangement status by the commercial probe were further clarified with no MECOM rearrangement in 2 cases and presence of a subclone with simultaneous gain and rearrangement of MECOM in 1 case. More importantly, the new probe is capable of determining the presence, location and integrity of MECOM after rearrangement. In conclusion, atypical signal patterns obtained using a commercial FISH probe for MECOM can be solved through re-design and optimization of a new BAP probe, especially in those cases with a true MECOM rearrangement. The potential of the new probe for use in the clinical laboratory will be further investigated.

KW - Fluorescence in situ hybridization (FISH)

KW - MECOM rearrangement

KW - Myeloid neoplasms

KW - Probe design

KW - “unbalanced” signal pattern

UR - http://www.scopus.com/inward/record.url?scp=85122332106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122332106&partnerID=8YFLogxK

U2 - 10.1016/j.cancergen.2021.12.009

DO - 10.1016/j.cancergen.2021.12.009

M3 - Article

C2 - 34974290

AN - SCOPUS:85122332106

SN - 2210-7762

VL - 262-263

SP - 23

EP - 29

JO - Cancer Genetics

JF - Cancer Genetics

ER -

Newly designed breakapart FISH probe helps to identify cases with true MECOM rearrangement in myeloid malignancies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this